{
  "docId": "019dd923-622c-750b-8b97-5cb48bf2a635",
  "docSlug": "b8afd3741673",
  "documentTitle": "Chinook Therapeutics Inc (KDNY)",
  "authorId": "51_Muddy_Waters",
  "authorName": "Carson C. Block",
  "documentKindSlug": "research-note",
  "documentKindLabel": "Research note",
  "sourceTypeSlug": "short_seller",
  "sourceTypeLabel": "Short seller",
  "presentationDate": "2023-05-16 00:00:00",
  "orientation": "portrait",
  "aspectRatio": 0.77272725,
  "pageNumber": 31,
  "pageCount": 36,
  "prevPage": 30,
  "nextPage": 32,
  "slideType": "appendix_data",
  "function": "analyze_data",
  "density": "dense",
  "nDataPoints": 30,
  "notes": "Includes critical commentary on the ALIGN trial and potential data obfuscation.",
  "elementsJson": [
    "headline_text",
    "bar_chart_vertical",
    "data_table",
    "paragraph",
    "footnote"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622c-750b-8b97-5cb48bf2a635/31",
  "deckHref": "/decks/019dd923-622c-750b-8b97-5cb48bf2a635",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b97-5cb48bf2a635.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b97-5cb48bf2a635#slide-31",
  "components": [
    {
      "bbox": {
        "h": 0.02,
        "w": 0.36,
        "x": 0.32,
        "y": 0.15
      },
      "kind": "callout",
      "text": "91% of patients achieved >40% reduction in proteinuria at Week 24",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3579aaf4-17eb-48d1-8a9a-312f210ebafc",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "callout",
      "text": "Chinook's other trial, the ALIGN trial, includes a placebo—perhaps this is why we Chinook has presented no data from it.",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd953-25b7-709e-b8d2-0fb7a94346f5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.5,
        "x": 0.25,
        "y": 0.18
      },
      "kind": "chart",
      "text": "UPCR Cumulative % Reduction at Week 12 and Week 24",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2421bb91-76e5-4dd3-b10c-38da0dd353f5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "metric",
      "text": "proteinuria reduction: 91%",
      "attrs": null,
      "subkind": "primary",
      "toolName": "Quantification",
      "toolSlug": "quantification",
      "confidence": null,
      "componentId": "019dd953-25b7-709e-b8d2-100e55d5559e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.78,
        "x": 0.11,
        "y": 0.64
      },
      "kind": "paragraph",
      "text": "Chinook's other trial, the ALIGN trial, includes a placebo—perhaps this is why we Chinook has presented no data from it.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "33c475b8-3b01-43b5-ab12-c08df31cb998",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.78,
        "x": 0.11,
        "y": 0.85
      },
      "kind": "source-note",
      "text": "Footnotes 156, 157, 158",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7ebd65ca-8613-4bbe-a1f1-528773837349",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.58,
        "x": 0.21,
        "y": 0.42
      },
      "kind": "table",
      "text": "AE Category and n (%) table",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "579f26da-514f-4ce5-becc-9fb5c857966c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.18,
        "x": 0.21,
        "y": 0.36
      },
      "kind": "title",
      "text": "Safety and Tolerability",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7bab38d8-50ea-42e5-a3b2-c8ee74c859e8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.58,
        "x": 0.21,
        "y": 0.1
      },
      "kind": "title",
      "text": "Atrasentan Provides Clinically Meaningful Proteinuria Reduction in Patients with IgAN Receiving Optimized SOC",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9680641d-e223-44ce-8295-15079bf35e1c",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 33,
      "from": 28,
      "beatId": "640ed796-f0a7-4d27-b017-41863f0ffedf",
      "arcName": "Overcoming the Monster",
      "arcSlug": "overcoming-monster",
      "beatName": "The Victory",
      "beatSlug": "overcoming-monster-the-victory",
      "evidence": "The report presents the 'victory' of Muddy Waters Research in uncovering the truth",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [
    {
      "to": 33,
      "from": 28,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "6980f318-c257-42fa-96be-f6e3de335b06",
      "evidence": "The report implies that investors and analysts should be cautious",
      "position": 1,
      "objective": "To highlight the consequences of not addressing the issues with the trial results",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}